Pancreatitis risk for patients on gliptins

A US study in 2600 patients with type 2 diabetes hospitalised for acute pancreatitis showed exenatide (Byetta) and sitagliptin (Januvia) were associated with double the risk of acute pancreatitis compared with controls.